Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease
Objective To investigate the humoral and cellular immune response to messenger RNA (mRNA)
COVID-19 vaccines in patients with immune-mediated inflammatory diseases (IMIDs) …
COVID-19 vaccines in patients with immune-mediated inflammatory diseases (IMIDs) …
COVID‐19 in patients with inflammatory arthritis: a prospective study on the effects of comorbidities and disease‐modifying antirheumatic drugs on clinical outcomes
RH Haberman, R Castillo, A Chen, D Yan… - Arthritis & …, 2020 - Wiley Online Library
Objective To characterize the hospitalization and death rates among patients with inflammatory
arthritis (IA) affected by coronavirus disease 2019 (COVID‐19) and to analyze the …
arthritis (IA) affected by coronavirus disease 2019 (COVID‐19) and to analyze the …
Evaluation of immune response and disease status in systemic lupus erythematosus patients following SARS–CoV‐2 vaccination
…, AR Cornelius, RS Herati, RH Haberman… - Arthritis & …, 2022 - Wiley Online Library
Objective To evaluate seroreactivity and disease flares after COVID‐19 vaccination in a
multiethnic/multiracial cohort of patients with systemic lupus erythematosus (SLE). Methods …
multiethnic/multiracial cohort of patients with systemic lupus erythematosus (SLE). Methods …
Spatial transcriptomics stratifies psoriatic disease severity by emergent cellular ecosystems
…, D Yan, P Konieczny, B Hsieh, RH Haberman… - Science …, 2023 - science.org
Whereas the cellular and molecular features of human inflammatory skin diseases are well
characterized, their tissue context and systemic impact remain poorly understood. We thus …
characterized, their tissue context and systemic impact remain poorly understood. We thus …
Methotrexate and TNF inhibitors affect long-term immunogenicity to COVID-19 vaccination in patients with immune-mediated inflammatory disease
RH Haberman, S Um, JE Axelrad, RB Blank… - The Lancet …, 2022 - thelancet.com
Studies have revealed that patients with immunemediated inflammatory diseases, especially
those on immunomodulatory medication, have attenuated immunogenicity to COVID-19 …
those on immunomodulatory medication, have attenuated immunogenicity to COVID-19 …
Efficacy of guselkumab, a selective IL-23 inhibitor, in preventing arthritis in a multicentre psoriasis at-risk cohort (PAMPA): protocol of a randomised, double-blind …
RH Haberman, KA MacFarlane, S Catron, J Samuels… - BMJ open, 2022 - bmjopen.bmj.com
Introduction Psoriatic arthritis (PsA) is a complex, immune-mediated disease associated with
skin psoriasis that, if left untreated, can lead to joint destruction. Up to 30% of patients with …
skin psoriasis that, if left untreated, can lead to joint destruction. Up to 30% of patients with …
Leveraging the United States epicenter to provide insights on COVID‐19 in patients with systemic lupus erythematosus
…, MY Kim, B Myers, RH Haberman… - Arthritis & …, 2020 - Wiley Online Library
Objective To characterize patients with systemic lupus erythematosus (SLE) affected by
coronavirus disease 2019 (COVID‐19) and to analyze associations of comorbidities and …
coronavirus disease 2019 (COVID‐19) and to analyze associations of comorbidities and …
Cardiovascular and venous thromboembolic risk with Janus kinase inhibitors in immune‐mediated inflammatory diseases: a systematic review and meta‐analysis of …
MH Maqsood, BN Weber, RH Haberman… - ACR Open …, 2022 - Wiley Online Library
Objective Janus kinase (JAK) inhibition effectively treats immune‐mediated inflammatory
diseases (IMIDs); however, concern over the risk of major adverse cardiac events (MACE) and …
diseases (IMIDs); however, concern over the risk of major adverse cardiac events (MACE) and …
Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study
LM Perez-Chada, RH Haberman, V Chandran… - Nature reviews …, 2021 - nature.com
The concept of psoriatic arthritis (PsA) prevention is gaining increased interest owing to the
physical limitation, poor quality of life and low remission rates that are achieved with current …
physical limitation, poor quality of life and low remission rates that are achieved with current …
Induction of remission in biologic-naive, severe psoriasis and PsA with dual anti-cytokine combination
RH Haberman, R Castillo, JU Scher - Rheumatology, 2021 - academic.oup.com
DEAR EDITOR, PsA is a complex and heterogeneous immune-mediated inflammatory arthritis
occurring in up to 30% of patients with psoriasis [1]. Despite the significant advances in …
occurring in up to 30% of patients with psoriasis [1]. Despite the significant advances in …
